ByHeart Baby Formula Linked to Botulism Outbreak in Infants

Preliminary tests have identified the presence of bacteria responsible for botulism in ByHeart baby formula, prompting urgent warnings from California health officials. At least 13 infants across 10 states have been reported ill due to the formula, although no fatalities have occurred. The California Department of Public Health issued a statement late Saturday advising consumers to cease using the product immediately.

ByHeart Whole Nutrition Infant Formula is currently under investigation by state and federal health authorities. The outbreak, which began in mid-August, has led to a recall of two specific lots of the powdered formula, which is labeled with a best-by date of December 2026.

Details of the Outbreak

The infant botulism outbreak has affected babies aged between 2 weeks and 5 months since its onset. According to the U.S. Centers for Disease Control and Prevention (CDC), all affected infants required hospitalization after consuming the ByHeart formula. The states involved include Arizona, California, Illinois, Minnesota, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas, and Washington.

California officials conducted tests on a can of the formula given to one of the sickened infants. The results indicated the potential presence of the bacteria that produces the botulinum toxin, similar to that found in other confirmed cases. Further testing is ongoing, and ByHeart has acknowledged the need for more analysis to determine whether the bacteria is present in their product.

Understanding Infant Botulism

Infant botulism occurs when a type of bacteria produces toxins in the large intestine. This condition typically affects fewer than 200 infants in the United States each year. The bacterium is commonly found in the environment, and infants can become ill after exposure to spores present in dust, dirt, or contaminated honey.

Symptoms include poor feeding, loss of head control, drooping eyelids, and a flat facial expression. Infants may appear “floppy” and struggle with swallowing or breathing. Notably, Dr. Steven Abrams, a nutrition expert from the University of Texas, stated that there have been no previous confirmed outbreaks of infant botulism linked to powdered formula, making this situation particularly rare.

Treatment for infant botulism is available through an intravenous medication known as BabyBIG, which is derived from the plasma of adults immunized against botulism. This treatment is developed by California’s Infant Botulism Treatment and Prevention Program and is the only source of such medication worldwide. All affected infants in this outbreak have received BabyBIG, as confirmed by the CDC.

Impact on Formula Supply and Regulatory Actions

Despite the seriousness of this outbreak, there is currently no risk of a nationwide formula shortage. ByHeart, founded in 2016, accounts for an estimated 1% of national formula sales, in contrast to the significant shortages experienced during the 2022 crisis linked to Abbott Laboratories. That crisis involved a different germ, leading to the closure of a major manufacturing plant and widespread product shortages.

Additionally, ByHeart faced scrutiny in 2022 when five batches of its infant formula were recalled after testing positive for cronobacter sakazakii, the germ implicated in the Abbott crisis. Recently, the FDA issued a warning letter to ByHeart detailing areas requiring corrective actions.

In light of these events, federal health officials are reevaluating the U.S. infant formula market. Health Secretary Robert F. Kennedy Jr. has directed the FDA to review the nutrients and other ingredients in infant formula. This initiative, referred to as “Operation Stork Speed,” represents the first comprehensive review of infant formula ingredients since 1998. The FDA is currently gathering input from industry experts and the public to determine the next steps.

The situation remains fluid as health officials continue to investigate the outbreak and further assess the safety of infant nutrition products.